SRX Global Provides Update on Engineered T-Cell Strategy Following Pfizer–Starna Licensing Agreement
Pfizer’s $330 million upfront commitment to three pre-IND in vivo CAR-T programs highlights pharmaceutical industry
Pfizer’s $330 million upfront commitment to three pre-IND in vivo CAR-T programs highlights pharmaceutical industry
NORTH PALM BEACH, Fla., Oct. 30, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or
UC Davis is the primary manufacturing site for CER-1236, site activation is expected to expand patient recruitment
New platform to be launched with managers from Millennium Management, Balyasny and Citadel, designed to enable the next
SPV, CERO 1236, to raise capital directly into subsidiary and not dilute existing SRX Global shareholders Proposed
SRX to dividend ETF holdings to shareholders Initial ETF to feature an actively managed digital asset hedging strategy
SRX has added ONCO in anticipation of Realbotix LLC acquisition closing. Believes Vinci AI Vision system is extremely
NORTH PALM BEACH, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or
NORTH PALM BEACH, Fla., Sept. 03, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or
The Debt investment is expected to accelerate development of CERo's lead therapeutic CER-1236 for hematological cancers
Net Asset Value ("NAV") of $62.9 million, or $3.22 per Common Share, Exceeding Preliminary Estimate of $3.07 per
NORTH PALM BEACH, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company”, or
